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Abstract  
Tacrolimus is a macrolide lactone antibiotic, and acts as a calcineurin inhibitor. It is widely used to prevent 
organ transplant rejection. It has been approved as first-line treatment after organ transplantation. Tacrolimus has 
narrow therapeutic range and wide individual variability in its phar¬macokinetics. In organ transplantation, 
immunosuppression is associated with important risks, in particular, related to infections and cardiovascular diseases, 
which are the predominant causes of death in those with a functioning graft. This review focuses on toxicity of 
tacrolimus after transplantation. Tacrolimus toxicity is a major determinant of morbidity and mortality in organ 
recipients after transplantation. Therefore, reducing toxicities has become a priority. To decrease the incidence of 
side effects, and expand graft survival, the appropriate initial and maintenance dose of tacrolimus is essential. Clinical 
conditions that influence tacrolimus pharmacokinetics, such as hemorrhage, systemic inflammation and shock, all 
result in higher variations of tacrolimus concentrations. In addition, unbound plasma concentration is a major 
important reasonable parameter for monitoring  of  receiving  optimal tacrolimus dosing in the unstable patient. 
Therefore, the approach of tacrolimus monitoring is vital and will support to avoid tacrolimus toxicity in the early 
days after transplantation. 
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Organ transplantation is the treatment of choice 
for terminal and irreversible organ failure. 
Development of immunosuppressive medications is 
the key to successful organ transplantation. 
Immunosuppressive drugs are used for maintenance 
and reversal of established rejection. In 1984, 
tacrolimus was isolated from the fermentation of 
Streptomyces, and was investigated as a novel 
immunosuppressant [1]. In 1994, the FDA accepted 
the use of tacrolimus for the prevention of rejection in 
liver transplantation [2, 3]. Its application has since 
expanded to other types of transplants, and today it is 
an important immunosuppressive used in transplant 
patients. The half-life of tacrolimus is 8.7-11.3 h [4-6]. 
Steady state concentrations are expected in two to three 
days. It has been shown that absorption of tacrolimus is 
unpredictable between individuals. After oral 
administration, tacrolimus is rapidly absorbed with 
mean time of peak concentrations of 1.5 to 2 hours. 
Bioavailability of tacrolimus is approximately 21%, 
although there is large individual instability [7].  
Tacrolimus has a wide range of toxicities. This article 
reviews toxicity of tacrolimus in organ transplantation. 
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Mechanism of tacrolimus 
Tacrolimus can cause impairment of gene 
expression in target cells. It binds to an immunophilin, 
FK506 binding protein 12 (FKBP12). This complex 
inhibits phosphatase activity of calcineurin. 
Calcineurin is a heterodimeric Ca2+/calmodulin-
stimulated protein phosphatase, consisting of a 
catalytic A subunit (CnA) and a tightly associated 
Ca2+-binding regulatory B subunit (CnB), and plays 
a key role in T-cell activation by regulating the activity 
of NFAT (nuclear factor of activated T cells) and 
calcium signaling [8]. Inhibition of calcineurin 
phosphatase suppresses translocation of an activated 
T-cell transcription factor that promotes interleukin-2-
mediated proliferation of helper T-cells, which plays a 
critical role in the immune response associated with 
allograft rejection [4]. 
Metabolism of Tacrolimus  
Cytochrome P450 3A4 (CYP3A4) is the major 
iso-enzyme involved in the metabolism of tacrolimus. 
Extended metabolism by CYP3A4 in the 
gastrointestinal tract is responsible for presystemic 
elimination of about half of the absorbed dose, 
whereas first-pass metabolism by CYP3A4 in the liver 
accounts for an additional 10% of elimination. The 
amount of absorption of tacrolimus from the 
gastrointestinal tract is also affected by the activity of 
P-glycoprotein (P-gp) in enterocytes. P-gp is encoded 
by the Multidrug Resistance Gene 1 (MDR1) [9, 10]. 
P-gp, an adenosine triphosphate (ATP)-driven efflux 
pump, is a transmembrane transporter that is closely 
associated with CYP3A4 and secretes tacrolimus and 
its metabolites back into the lumen of the gut. The 
expression of Pgp and CYP3A can be influenced by 
genetics [11, 12].  
Side effects of Tacrolimus  
Tacrolimus is associated with nephrotoxicity, 
neurotoxicity, gastrointestinal toxicity, hyperkalemia, 
hypertension, myocardial hypertrophy, 
hyperlipidemia and a higher incidence of new-onset 
diabetes mellitus after transplantation [13-17]. 
Tacrolimus induced nephrotoxicity  
Tacrolimus can cause acute and chronic 
nephrotoxicity [18]. It has been illustrated that in 17 to 
44% of renal transplant recipients and in 18 to 42% of 
liver transplant recipients undergo chronic renal 
failure within 5 years [19, 20]. The occurrence of 
nephrotoxicity have not been systematically studied in 
Heart and lung, transplant recipients. Tacrolimus 
nephrotoxicity can be best managed by either 
discontinuation or reduction of the medication [21, 22]. 
The molecular mechanism of tacrolimus nephrotoxicity 
is not fully understood. It has been shown that 
tacrolimus binding proteins are present at a high 
concentration in the kidney. Vascular endothelial cells, 
tubular epithelial cells, interstitial fibroblasts, and 
arteriolar myocytes are targets for tacrolimus 
nephrotoxicity. Vasospasm results in decreased 
glomerular filtration, may have a key factor in the 
vascular toxicity of tacrolimus. The occurrence of 
epithelial and arteriolar myocyte vacuolization suggests 
a direct toxic effect of the drug on the renal tubule and 
smooth-muscle cells [13, 23]. 
It has also been reported that higher 
concentrations of 15-O-demethyl (M-III), one of major 
tacrolimus metabolites, may have a nephrotoxic or 
myelotoxic effect and result in higher incidence of 
infections [24]. 
Tacrolimus induced neurotoxicity  
It has been shown that tacrolimus induced 
neurotoxicity in 20% to 40% of solid organ transplant 
recipients [25]. The clinical appearance of tacrolimus 
neurotoxicity varies from headaches and tremors to 
confusion, agitation, hallucinations or overt psychosis. 
Although the molecular mechanism of tacrolimus 
neurotoxicity is less well understood, but there is 
evidence that it may be similar to hypertensive 
encephalopathy. On the other hand, not all patients with 
immunosuppressive induced leukoencephalopathy 
have hypertension [26]. 
Hypertension is one of the most common 
adverse effects of tacrolimus. Hypertension is as a risk 
factor for posterior reversible encephalopathy 
syndrome (PRES), a rare, but serious side effect of 
tacrolimus therapy [14].  
The pathophysiology of PRES is still unknown, 
but there are some theories. PRES seems to be related 
to impaired cerebral autoregulation and dysfunction of 
the cerebrovascular blood–brain barrier [27]. Cerebral 
autoregulation can be defined the maintenance of 
constant blood flow to the brain by vasoconstriction or 
vasodilatation of resistance arterioles, resulting in a 
constant blood flow to the brain. Acute elevation of 
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blood pressure could overcome the capacity of the 
normal autoregulation. This can cause cerebral 
vasodilation with a resulting hyperperfusion and/or 
regional vasoconstriction of the brains arteries. 
Hyperperfusion could lead to endothelial dysfunction, 
resulting in an extravasation of proteins and fluid, i.e., 
causing a vasogenic edema. Therefore, controlling 
blood pressure to near baseline levels may play a 
critical role in minimizing neurological toxicities of 
tacrolimus during the transplant process [27-29]. 
It is important to mention that tacrolimus is 
lipophilic, but it does not cross the blood-brain barrier 
(BBB) because the P-glycoprotein efflux pump may 
block its entry. In some people, a polymorphism in the 
MDR1 gene causes a reduction or loss in efflux pumps 
allowing tacrolimus to enter the BBB. Brain myelin 
has a high lipid content which may be a preferential 
binding site for tacrolimus. Studies in stem cell 
transplant and organ transplant patients taking 
tacrolimus have shown a correlation between patients 
with MDR1 polymorphisms and neurotoxicity with 
tacrolimus [30-32].  
Tacrolimus induced hypertension 
In organ transplantation, hypertension is an 
important risk factor for allograft vasculopathy, 
peripheral artery disease, and decreased allograft and 
patient survival [33, 34].  
The mechanisms responsible for tacrolimus 
induced hypertension are not completely understood 
but are believed to initiate in the vasculature. 
Endothelial dysfunction and more specifically 
a decrease in production of the vasodilator nitric oxide 
(NO) by endothelial NO synthase (eNOS) probably 
play a primary role in the pathogenesis of 
hypertension [35]. 
Studies have considered the role of endothelial 
dysfunction and NO bioavailability in tacrolimus-
induced hypertension. It has been demonstrated that 
two weeks treatments of rats with tacrolimus increases 
systolic blood pressure and decreases mesenteric 
endothelium-dependent relaxation responses, as well 
as aortic eNOS activity [36, 37].  
The production of NO from eNOS is mediated 
by the Ca2+/calmodulin and is regulated by multiple 
factors, including changes in phosphorylation 
condition [38]. 
Tacrolimus inhibits FKBP12/12.6 in blood 
vessels leading to reduced vasodilation and/or 
increased vasoconstriction [15]. It is illustrated that 
FKBP12.6 deficient mice develop hypertension, and 
genetic and pharmacologic removal of FKBP12/12.6 
from intracellular calcium channels dose-dependently 
decreases nitric oxide production and endothelial 
function [39]. In addition to its negative effects on 
endothelial nitric oxide production, tacrolimus 
increases transforming growth factor-β (TGF-β) levels 
and elevated levels of TGF-β are associated with 
hypertension [40].  
Tacrolimus induced myocardial 
hypertrophy 
Cardiotoxicity due to tacrolimus is a lethal 
complication after organ transplantation. Decreasing 
the tacrolimus trough concentration or changing 
tacrolimus therapy to another immunosuppressive 
therapy caused regression or improvement in cardiac 
involvement. 
A number of mechanisms have been suggested 
to explain the cardiotoxicity of tacrolimus. It is 
demonstrated that tacrolimus changes intracellular 
calcium handling and causes myocardial hypertrophy. 
FK506 binding protein is expressed in skeletal and 
cardiac muscles. FK506 binding protein stabilizes the 
ryanodine receptor. Ryanodine receptor is an 
intracellular calcium release channel in the terminal 
cisternae of the sarcoplasmic reticulum of muscle and 
non-muscle cells [41].  
In presence of tacrolimus, FK506 binding 
protein binds to tacrolimus and is released from the 
ryanodine receptor, thus increasing calcium release 
from the sarcoplasmic reticulum. It has been shown that 
calcium overload associated with the onset and 
progression of cardiac hypertrophy [42]. In addition, 
tacrolimus may induce capillary leak syndrome, and 
causes interstitial edema followed by myocardial 
hypertrophy in rabbits. Tacrolimus resulted vasculitis in 
several dogs and baboon organs, including the heart 
[43]. This vasculitis may be related to the myocardial 
toxicity of tacrolimus. Although it is an important 
immunosuppressive drug in organ transplantation, 
blood concentration must be carefully maintained [44]. 
It is likely that the cardiotoxicity associated with 
tacrolimus is related to high blood levels of this 
medication, particularly at levels greater than 20 ng/mL 
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[16]. 
Repeated echocardiography is helpful to detect 
and avoid tacrolimus-induced cardiac hypertrophy 
[44]. 
Tacrolimus induced diabetes 
mellitus   
Tacrolimus can cause diabetes mellitus after 
transplantation. It prevents the transcription of the 
insulin gene in the beta-cell via inhibition of 
calcineurin after binding to FKBP12 [45]. The 
FKBP12 is highly concentrated in the B cells of the 
pancreas. Tacrolimus leads to decreased insulin 
synthesis, secretion and sensitivity [46]. Tacrolimus 
impairs the glucose uptake in cells due to a reduction 
in the number of glucose transporter type 4 (GLUT-4) 
receptor molecules on the cell membrane surface of 
adipocytes [47]. GLUT-4 is the insulin-regulated 
protein present primarily in adipose tissue and striated 
muscle, providing the translocation of glucose into the 
cell [48].  
Thus, failure in GLUT-4 translocation leads to 
hyperglycemia. Tacrolimus also decreases 
glucokinase activity in pancreatic islets, thereby 
suppressing glucose-induced insulin release [49]. 
It has also been demonstrated that Tacrolimus 
can cause islet cell injury in the form of cytoplasmic 
swelling, vacuolization, and altered insulin staining 
[17]. Moreover, it has been shown that, Tacrolimus 
treatment resulted in dose- and time-dependent 
increases in the production of reactive oxygen species 
by beta cells. In addition, the antioxidant status 
decreased in beta cells after tacrolimus treatment. 
(57). 
High concentration of tacrolimus, elder age, 
family history for diabetes mellitus are the most 
significant risk factors for the development of post-
transplant diabetes mellitus. Diabetes mellitus is a 
severe complication as it may cause weight loss, 
infections, and cardiac allograft vasculopathy that is 
associated with increased rejection risk [46]. 
However, the diabetogenicity of tacrolimusis often 
reversible with dosage reduction of tacrolimus [54]. 
It has been shown that mesenchymal stem cell 
(MSCs) transplantation is a new approach to control 
hyperglycemia in diabetes mellitus [50, 51]. In 
addition, inhibition of oxidative stress may block both 
the initiation and progression of diabetic complications 
[52, 53]. Interestingly, it has been demonstrated that 
therapeutic concentrations of immunosuppressive 
drugs affect MSCs function. MSCs also affect the 
efficacy of immunosuppressive medication such as 
Tacrolimus. These findings may be important for 
potential clinical use of MSC in combination with 
immunosuppressant, so that preincubation/pretreatment 
of MSC with Tacrolimus increased the 
immunosuppressive capacity of MSC. (58). 
Conclusions and Future 
Perspectives 
Tacrolimus has a narrow therapeutic window, 
and its blood concentration should be maintained at an 
optimal range in transplanted patients for the following 
reasons. If the concentration is inadequate, the 
transplanted organ will be rejected as a result of the 
insufficient immunosuppression by tacrolimus. If the 
concentration is greater than therapeutic range, adverse 
effects will be observed due to the excess concentration 
of tacrolimus [55].  
Tacrolimus has significant inter-individual and 
intra-individual pharmacokinetic variability that makes 
it impossible to give a standard dosing regimen to all 
adults to achieve target blood concentrations. 
Therapeutic drug monitoring (TDM) and 
pharmacokinetic based design of individualized dosage 
regimens are recommended to optimize treatment 
outcome. TDM in transplanted patients is conducted by 
measuring the whole blood levels of tacrolimus by an 
enzyme immunoassay (EIA) using the monoclonal 
antibody raised against tacrolimus [56]. 
It could be suggested that co administration of 
immunosuppresant drugs like Tarolimus with 
mesenchymal stem cell may potentiate Tacrlimus 
immunosuppresive effect in addition to enhancing 
MSCs intrinsic immunomodulatory/immuosuppressive 
effect to prevent rejection in a synergistic pattern. 
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